VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) (the “Company” or “GoldHaven”) is pleased to announce that it has closed its previously announced non-brokered flow-through financing (the “Flow-Through Offering”) through the issuance of 3,773,584 flow-through common shares (the “FT Shares”) at a price of $0.265 per FT Share for aggregate proceeds of $1 million.

Originally published via Source Article.

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) (the “Company” or “GoldHaven”) is pleased to announce that it has closed its previously announced non-brokered flow-through financing (the “Flow-Through Offering”) through the issuance of 3,773,584 flow-through common shares (the “FT Shares”) at a price of $0.265 per FT Share for aggregate proceeds of $1 million.

Originally published via Source Article.

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) (the “Company” or “GoldHaven”) is pleased to announce that it has closed its previously announced non-brokered flow-through financing (the “Flow-Through Offering”) through the issuance of 3,773,584 flow-through common shares (the “FT Shares”) at a price of $0.265 per FT Share for aggregate proceeds of $1 million.

Originally published via Source Article.

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) (the “Company” or “GoldHaven”) is pleased to announce that it has closed its previously announced non-brokered flow-through financing (the “Flow-Through Offering”) through the issuance of 3,773,584 flow-through common shares (the “FT Shares”) at a price of $0.265 per FT Share for aggregate proceeds of $1 million.

Originally published via Source Article.

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) (the “Company” or “GoldHaven”) is pleased to announce that it has closed its previously announced non-brokered flow-through financing (the “Flow-Through Offering”) through the issuance of 3,773,584 flow-through common shares (the “FT Shares”) at a price of $0.265 per FT Share for aggregate proceeds of $1 million.

Originally published via Source Article.

VANCOUVER, British Columbia, Oct. 08, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) (the “Company” or “GoldHaven”) is pleased to announce that it has closed its previously announced non-brokered flow-through financing (the “Flow-Through Offering”) through the issuance of 3,773,584 flow-through common shares (the “FT Shares”) at a price of $0.265 per FT Share for aggregate proceeds of $1 million.

Originally published via Source Article.

VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced that it will participate in the ThinkEquity Conference taking place on October 15, 2026, at the Mandarin Oriental Hotel in New York City. Management will present a corporate overview at 4:00 p.m. Eastern time and will be available for one-on-one meetings with investors registered for the event.

Originally published via Source Article.

VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced that it will participate in the ThinkEquity Conference taking place on October 15, 2026, at the Mandarin Oriental Hotel in New York City. Management will present a corporate overview at 4:00 p.m. Eastern time and will be available for one-on-one meetings with investors registered for the event.

Originally published via Source Article.

VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced that it will participate in the ThinkEquity Conference taking place on October 15, 2026, at the Mandarin Oriental Hotel in New York City. Management will present a corporate overview at 4:00 p.m. Eastern time and will be available for one-on-one meetings with investors registered for the event.

Originally published via Source Article.

VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (FSE: 8BN) (“Optimi” or “the Company”), a commercial-stage pharmaceutical manufacturer and clinical-stage developer of regulated psychedelic drug products, today announced that it will participate in the ThinkEquity Conference taking place on October 15, 2026, at the Mandarin Oriental Hotel in New York City. Management will present a corporate overview at 4:00 p.m. Eastern time and will be available for one-on-one meetings with investors registered for the event.

Originally published via Source Article.